Literature DB >> 10741622

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects.

H Takanaga1, A Ohnishi, H Murakami, H Matsuo, S Higuchi, A Urae, S Irie, H Furuie, K Matsukuma, M Kimura, K Kawano, Y Orii, T Tanaka, Y Sawada.   

Abstract

A clinical study was performed in eight healthy volunteers to investigate the effect of various timing of grapefruit juice intake on nisoldipine pharmacokinetics and pharmacodynamics, and to validate our pharmacokinetic model. The subjects were given 10 mg oral nisoldipine with water (control), or 5 mg oral nisoldipine with 200 mL grapefruit juice (G0) or with water at 14 (G14), 38 (G38), 72 (G72) or 96 hours (G96) after a 7-day period of thrice-daily intake of grapefruit juice. Grapefruit juice ingestion did not affect heart rate or the effect area during the first 8 hours of heart rate after nisoldipine administration, although significant decreases of systolic and diastolic blood pressure were caused in G0 by coadministration of grapefruit juice with nisoldipine. Headaches were reported by 3, 2, and 1 persons in G0, G14, and G38, respectively, but no subjects in G72 and G96 reported headaches. Compared with the control group, the maximum plasma concentration of nisoldipine was significantly increased after grapefruit juice intake in G0 and G14, and the plasma concentration was significantly increased at each time in G0 to G72. Therefore the effect of grapefruit juice decreased time dependently and lasted for at least 3 days after intake. Furthermore, our model gave predicted values in good agreement with the observed values. It is therefore necessary to withhold grapefruit juice for at least 3 days before administration of the drug to prevent grapefruit juice-nisoldipine interaction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741622     DOI: 10.1067/mcp.2000.104215

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

3.  Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Shinji Miyake; Ryuichi Hasegawa
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

4.  Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists.

Authors:  Ayako Ohnishi; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 5.  The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.

Authors:  D L Whitten; S P Myers; J A Hawrelak; H Wohlmuth
Journal:  Br J Clin Pharmacol       Date:  2006-09-29       Impact factor: 4.335

6.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

Review 7.  Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

Authors:  Carl J Fichtenbaum; John G Gerber
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Grapefruit-medication interactions: forbidden fruit or avoidable consequences?

Authors:  David G Bailey; George Dresser; J Malcolm O Arnold
Journal:  CMAJ       Date:  2012-11-26       Impact factor: 8.262

9.  Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.

Authors:  Garrett R Ainslie; Kristina K Wolf; Yingxin Li; Elizabeth A Connolly; Yolanda V Scarlett; J Heyward Hull; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2014-09-24       Impact factor: 4.030

10.  Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

Authors:  Ronald de Vries; Johan W Smit; Peter Hellemans; James Jiao; Joseph Murphy; Donna Skee; Jan Snoeys; Juthamas Sukbuntherng; Maarten Vliegen; Loeckie de Zwart; Erik Mannaert; Jan de Jong
Journal:  Br J Clin Pharmacol       Date:  2016-01-15       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.